How to Value a Medical Coding Business in 2026

Medical coding is the most interesting healthcare services niche to value right now, and I mean that in the way an M&A banker finds things interesting: there's genuine uncertainty about what these businesses are worth because the underlying technology is changing fast. Two years ago, coding companies were trading at 6-8x EBITDA like clockwork. Today the range is 4-7x, and the spread has a lot to do with how buyers model AI disruption risk.

I've been tracking coding company transactions closely since GPT-4 demonstrated real aptitude on ICD-10 and CPT assignment. The headlines said coders were about to be automated. The reality is messier and more interesting, and it's creating a bifurcated market where some coding businesses are still getting strong exits and others are struggling to find buyers at any price.

The New Multiple Range

Pre-2023, I would have told you medical coding businesses traded at 5-8x EBITDA depending on size, client mix, and certification depth. The 2024-2025 deals I've seen tell a different story. The current range:

• Sub-$500K EBITDA, commodity outsourced coding: 3-4x EBITDA. Buyers see this as a wasting asset.
• $500K-$2M EBITDA, diversified specialty coding: 4-6x EBITDA. Still attractive but discounted for disruption risk.
• $2M+ EBITDA with technology platform: 6-8x EBITDA. The AI concern flips to an AI opportunity if you own the tooling.
• Niche specialty with clinical expertise: 6-9x. Inpatient coding, HCC risk adjustment, and surgical coding still command premiums.

The biggest swing factor is whether a buyer sees your business as a labor arbitrage operation that's about to get compressed, or a domain expertise operation with a technology layer. The same company with $1.5M EBITDA can be worth $6M or $12M depending on how you position it.

Certification Depth Still Matters

AAPC and AHIMA certifications are the credentialing backbone of the industry. Buyers pull certification rosters during diligence and they care about the mix. A coding company where 60% of staff hold CPC (Certified Professional Coder) and 40% hold specialty credentials (CPMA, CIRCC, CPC-I, CCS-P) is worth more than one with 95% generalist certifications.

Why? Specialty-certified coders are hard to replace, command premium billing rates, and tend to work on higher-value claim types (surgical, interventional radiology, oncology) that AI handles less reliably. Inpatient facility coding with CCS-credentialed staff is probably the most defensible corner of the industry right now — the complexity of MS-DRG assignment and present-on-admission indicators has kept automation from fully penetrating.

I'd encourage anyone building a coding business toward an exit to track credentialing as a KPI and publish it in management reports. It's the kind of detail that looks thoughtful in diligence and supports the specialty-expertise narrative buyers want to see.

The AI Conversation You Need to Have

Every single buyer will ask you the AI question. How you answer determines whether you're getting 4x or 7x. The wrong answer is "we don't think AI will affect us." The right answer is a specific, evidence-based narrative about what you've built, what you're piloting, and where human coders remain essential.

The credible positions I've seen sellers take:

Hybrid workflow. You've integrated an autonomous coding engine (3M CodeRyte, Nym Health, Fathom, or an internal model) for high-volume, low- complexity claim types — and redeployed your coders toward audit, denial management, and complex inpatient work. This story supports 5-7x EBITDA because you're not fighting the technology, you're monetizing it.

Complexity specialization. Your book is concentrated in work types where AI accuracy still runs 70-85% (HCC risk adjustment, interventional procedures, evaluation and management with heavy documentation review). You can point to client audit results showing human coders outperform AI on your specific workload. This supports 6-8x because the disruption timeline is genuinely longer.

Platform play. You've built workflow software — even if it's just a sophisticated queue management and QA layer — and you're licensing it or selling coding-as-a-service rather than pure labor. See how to present technology investment in adjusted EBITDA for the diligence framing.

Who's Buying Coding Businesses in 2026

The buyer pool has thinned since 2022, but there are still active acquirers:

• RCM platforms: R1 RCM, Ensemble Health Partners, Conifer Health, and Savista add coding capacity through acquisition. They pay 5-7x for clean tuck-ins.
• Specialty coding consolidators: Aviacode (acquired by GeBBS), Maxim Healthcare Services, and Guidehouse have been active in specialty rollups.
• Offshore-onshore hybrids: GeBBS Healthcare, Access Healthcare, and Omega Healthcare acquire US-based coding shops to expand their onshore footprint for clients who require it.
• AI coding startups: Nym Health, Fathom, and CodaMetrix have raised meaningful capital and occasionally acquire traditional coding firms to get client relationships and training data.

The AI-native buyers are an interesting twist. They'll sometimes pay above-market multiples for coding businesses because they're really buying the client contracts and the coder training data, not the labor pool. If your business has dense documentation of coder decisions (rationale notes, edit trails, QA review), that's suddenly worth something it wasn't two years ago.

Client Quality Matters More Than Ever

In a disrupted market, buyers pay for client quality because they're skeptical about pricing power going forward. Hospital clients are worth more than physician group clients because hospital contracts run 3-5 years and include volume minimums. Multi-specialty clients are worth more than single-specialty because they're stickier. Risk-bearing entities (ACOs, MA plans) are worth the most because their coding needs are complex and compliance-sensitive.

Client concentration rules still apply: top client under 20%, top five under 50%. But I'd add a new metric buyers are asking about: what percentage of your clients have tried AI coding and stayed with you? That's the single most predictive answer about future revenue stability, and savvy sellers now volunteer it in confidential information memoranda.

What Kills These Deals

The failure modes I see most often:

Commodity positioning. If your pitch is "we do coding cheaper than the competition," you're getting 3-4x at best. Labor arbitrage stories don't survive diligence anymore.

Flat or declining productivity. Buyers want to see coder productivity (charts per hour, RVUs per coder) trending up, which proves you're capturing technology efficiency gains. Flat productivity over three years signals operational stagnation.

Audit problems. A single RAC audit finding or a documented payer dispute about upcoding can kill a deal. Buyers' diligence pulls compliance histories aggressively.

Offshore exposure without disclosure. If you're subcontracting to offshore coders without client knowledge or BAA compliance, it comes out in diligence. Clean it up before going to market.

The Bottom Line

Medical coding in 2026 is a tale of two businesses. The commodity shop is getting crushed. The specialty expertise shop with a technology story is still getting strong exits. If you're 18-36 months from a sale, spend that time investing in credentialing depth, documenting your technology layer even if it's modest, and tilting your client book toward complex work types. The multiple expansion from being positioned correctly is worth far more than any cost savings from cutting investment.